CAJ | 학술논문

目的：探讨高级别脑胶质瘤术后不同放化疗时序及程序对无进展生存期的影响。方法选择我院2011-05-2013-05收治的高级别脑胶质瘤患者80例，随机分为2组，分别给予放化疗＋化疗以及早期化疗＋同步放化疗＋辅助化疗。观察记录2组临床疗效，并进行比较。结果经COX多因素分析，病理分级、KPS评分、术前抽搐、肿瘤切除范围对患者的预后存在影响（均 P＜0.05）；治疗5个月，2组CBR比较差异无统计学意义（P＞0.05）；治疗8个月，2组CBR比较差异有统计学意义（P＜0.05）；2组中位OS比较差异无统计学意义（P＞0.05）；2组中位PFS比较差异有统计学意义（P＜0.05）。结论高级别脑胶质瘤术后予以早期化疗＋同步放化＋辅助化疗可有效延长患者的无进展生存期。
목적：탐토고급별뇌효질류술후불동방화료시서급정서대무진전생존기적영향。방법선택아원2011-05-2013-05수치적고급별뇌효질류환자80례，수궤분위2조，분별급여방화료＋화료이급조기화료＋동보방화료＋보조화료。관찰기록2조림상료효，병진행비교。결과경COX다인소분석，병리분급、KPS평분、술전추휵、종류절제범위대환자적예후존재영향（균 P＜0.05）；치료5개월，2조CBR비교차이무통계학의의（P＞0.05）；치료8개월，2조CBR비교차이유통계학의의（P＜0.05）；2조중위OS비교차이무통계학의의（P＞0.05）；2조중위PFS비교차이유통계학의의（P＜0.05）。결론고급별뇌효질류술후여이조기화료＋동보방화＋보조화료가유효연장환자적무진전생존기。
Objective To investigate the effect of different chemoradiotherapy sequences and schedules on progression-free survival after surgery of high-grade glioma.Methods Eighty patients with high-grade glioma who were admitted into our hospi-tal during May 2011 and May 2013 were randomly selected and were randomized into two groups to receive chemoradiotherapy+chemotherapy and early chemotherapy+concurrent chemoradiotherapy+adjuvant chemotherapy ,respectively.Clinical efficacy of the two groups was observed ,recorded and compared.Results There were no differencs between the general data of patients in the two groups (P>0 .05).COX multiple factor analysis showed that patients'prognosis was associated with pathological grading ,KPS scores ,preoperative convulsion and tumor resection range (P<0 .05). There was no statistically significant differ-ence in CBR between the two groups after 5 months of treatment (P>0.05) ,while statistically significant difference was found after 8 months of treatment (P< 0.05). No statistically significant difference was observed in median OS between the two groups (P>0.05). Statistically significant difference was found in median PFS between the two groups (P<0.05).Conclusion Progression-free survival was effectively prolonged in patients with high-grade glioma who received early chemotherapy + concurrentchemoradiotherapy + adjuvant chemotherapy after surgery.